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2.8 doses). Approximately 20% (86/448) of the total
available patient-days in this 2-week period were sub-
optimally treated due to missed doses. Five percent of
sub-optimal patient-days were the result of missing all 3
daily doses; 2% were due to missing 2 doses; and 93%
were due to missing 1 dose. The 3rd dose was most com-
monly missed. Forgetfulness was the main reason for
missing doses. A once-daily MPH formulation adminis-
tered in the morning could have decreased the number of
sub-optimal patient-days to 4%. CONCLUSIONS: The
extent of compliance with TID MPH is not ideal. A once-
daily formulation may help optimize MPH therapy in
children with ADHD.
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OBJECTIVES: Adopting new medical therapies is a
complex decision that must take into account many
factors, including differences in efﬁcacy, tolerability,
safety, pharmacokinetic properties, and costs. Long-term,
comparative clinical trials and economic evaluations of
newer antiepileptic drugs (AEDs) are lacking, therefore
decision models are needed to guide treatment decisions.
We aimed to develop an economic model of treatment of
newly diagnosed epilepsy in the UK, and to provide the
ﬁrst assessment of topiramate, a newer AED, in this
setting. METHODS: A Markov model was developed to
combine data from published clinical trials, cost-of illness
studies, epilepsy-related mortality surveys, and utility
studies. The expected costs and utilities associated with
possible treatment strategies (1st and 2nd line treatments)
for newly diagnosed epilepsy were calculated and com-
pared. A probabilistic analysis was undertaken and the
cost-effectiveness frontier mapped. Treatment strategies
for partial and generalised seizures were examined sepa-
rately. RESULTS: First and second-line monotherapy
with topiramate or carbamazepine in partial seizures
dominated (less costly and more effective) the other sce-
narios (ﬁrst and second-line monotherapy with lamotrig-
ine or carbamazepine, or lamotrinige or topiramate), 
and had the highest probability of being optimal over 
any value of the ceiling ratio. In generalised seizures
monotherapy with valproate followed by second-line
treatment with topiramate was the least costly option,
and had the highest probability of being cost-effective at
low values of the ceiling ratio (<£6600). In all other cases
ﬁrst line topiramate was cost-effective with valproate or
lamotrigine as second line treatment. CONCLUSIONS:
In the absence of head to head studies, economic models
provide a relevant framework within which costs and
health gains of AED treatment options can be studied.
Our ﬁndings suggest that topiramate is a cost-effective
monotherapy treatment for newly diagnosed epilepsy
patients with partial or generalised seizures.
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OBJECTIVES: To determine the 2-year incremental cost-
effectiveness and the welfare consequences of initial
pramipexole treatment compared with initial levodopa
treatment in patients with early Parkinson’s disease (PD).
METHODS: Three hundred one subjects with early PD
were randomized to either initial pramipexole or initial
levodopa and followed every 3-months over a 2-year
period. Subjects recorded all medical resource use on a
health care utilization diary. Costs were assigned to health
utilization data using a variety of methods. To estimate
health state preferences, we used the EuroQol system and
a visual analog scale (VAS) measured at baseline, and 10,
26, 52, 78, and 102 weeks after randomization. We
analyze and interpret data on cost-effectiveness using 
net-beneﬁt approach with different values of k, economic
value of QALY. RESULTS: For the ﬁrst 2 years of treat-
ment, initial pramipexole strategy is an estimated $1925
(SE $989) more expensive than initial levodopa strategy.
The pramipexole therapy cost $96,250 per QALY gained
in relation to levodopa when using EuroQol, but was
dominated by levodopa (i.e., less effective and more
costly) when using the VAS. Using the EuroQol, there is
a 0.33 probability that pramipexole is welfare-enhancing
when k = $50,000, a 0.51 probability when k = $100,000,
and a probability approaching 0.70 at very high valua-
tions of k (>$500,000). Using the VAS, there is a 0.07
probability that pramipexole is welfare-enhancing when
k = $50,000, a 0.15 probability when k = $100,000, and
a probability approaching 0.30 at very high valuations of
k (>$500,000). CONCLUSIONS: Although considerable
uncertainty exists in the 2-year cost-effectiveness of initial
pramipexole compared with initial levodopa in the treat-
ment of early PD, our estimates suggest that pramipexole
may not be welfare enhancing during the ﬁrst 2-years 
of treatment. If initial pramipexole results in long-term
improvements in quality of life, its cost-effectiveness will
become more favorable.
